In the absence of CTLA4 (−)/PD-1 (−) inhibitors, cluster 2 (SL-CRC) patients exhibited higher scores, suggesting they may have a stronger natural immune response or a more active immune state (Figure 5A). This evidence concerns the gene CTLA4 and colorectal carcinoma.